Pathophysiology of bone metastases in prostate cancer

European Urology, Supplements

Volumn 3, Issue 5 SPEC. ISS., 2004, Pages 3-9

  Abrahamsson, Per Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bisphosphonates; Bone metastases; Prostate cancer; Zoledronic acid

Indexed keywords

BONE DERIVED GROWTH FACTOR; ENDOTHELIN 1; INTERLEUKIN 6; PARATHYROID HORMONE RELATED PROTEIN; PROTEINASE ACTIVATED RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; ZOLEDRONIC ACID;

BONE METASTASIS; BONE REMODELING; CANCER CELL; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; RISK;

EID: 7244224968     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2004.09.001     Document Type: Conference Paper

References (46)

1. R.E. Coleman Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 2001 165 176
2. G.R. Mundy Mechanisms of bone metastasis Cancer 80 suppl 1997 1546 1556
3. C.T. McMurtry, and J.M. McMurtry Metastatic prostate cancer: complications and treatment J Am Geriatr Soc 51 2003 1136 1142
4. M.J. Morris, and H.I. Scher Clinical approaches to osseous metastases in prostate cancer Oncologist 8 2003 161 173
5. T.A. Guise, and G.R. Mundy Cancer and bone Endocr Rev 19 1998 18 54
6. S. Nomura, and T. Takano-Yamamoto Molecular events caused by mechanical stress in bone Matrix Biol 19 2000 91 96
7. A. Boyde The real response of bone to exercise J Anat 203 2003 173 189
8. G.R. Mundy Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 2002 584 593
9. S.S. Padalecki, M. Carreon, B. Grubbs, Y. Cui, and T.A. Guise Androgen deprivation enhances bone loss and prostate cancer metastases to bone: prevention by zoledronic acid Oncology 17 suppl 2003 32
10. -/-mice are protected from osteolytic bone metastases Oncology 17 suppl 3 2003 16 17
11. A. Berruti, P. Sperone, G. Fasolis, M. Torta, D. Fontana, and L. Dogliotti Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancer Prostate 33 1997 252 255
12. P. Langenstroer, R. Tang, E. Shapiro, B. Divish, T. Opgenorth, and H. Lepor Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies J Urol 150 1993 495 499
13. J.B. Nelson, S.P. Hedican, D.J. George, A.H. Reddi, S. Piantadosi, and M.A. Eisenberger Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate Nat Med 1 1995 944 949
14. J.B. Nelson, A.A. Nabulsi, N.J. Vogelzang, J. Breul, B.A. Zonnenberg, and D.D. Daliani Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan J Urol 169 2003 1143 1149
15. A. Lipton Management of metastatic bone disease and hypercalcemia of malignancy Am J Cancer 2 2003 427 438
16. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, and L. Lacombe A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
17. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J.L. Chin, J.J. Vinholes, J.A. Goas, M. Zheng for the Zoledronic Acid Prostate Cancer Study Group Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
18. Saad F, Gleason D, Murray R, Venner P, Goas JA, Chen B-L, et al. Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone [poster]. Presented at: American Urological Association; April 26-May 1, 2003; Chicago, Ill. Abstract 1473.
19. A.A. Geldof Models for cancer skeletal metastasis: a reappraisal of Batson's plexus Anticancer Res 17 1997 1535 1539
20. C.R. Cooper, C.H. Chay, J.D. Gendernalik, H.L. Lee, J. Bhatia, and R.S. Taichman Stromal factors involved in prostate carcinoma metastasis to bone Cancer 97 suppl 2003 739 747
21. D.A. Walz, and J.W. Fenton The role of thrombin in tumor cell metastasis Invasion Metastasis 14 1994-1995 303 308
22. M.A. Lafleur, M.D. Hollenberg, S.J. Atkinson, V. Knauper, G. Murphy, and D.R. Edwards Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species Biochem J 357 2001 107 115
23. V.I. Romanov, and M.S. Goligorsky RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro Prostate 39 1999 108 118
24. S.L. Teitelbaum Bone resorption by osteoclasts Science 289 2000 1504 1508
25. I. Pécheur, O. Peyruchaud, C.M. Serre, J. Guglielmi, C. Voland, and F. Bourre Integrin α(v)β3 expression confers on tumor cells a greater propensity to metastasize to bone FASEB J 16 2002 1266 1268
26. M. Bezzi, M. Hasmim, G. Bieler, O. Dormond, and C. Rüegg Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death. Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt J Biol Chem 278 2003 43603 43614
27. P. Heikkila, O. Teronen, M. Moilanen, Y.T. Konttinen, R. Hanemaaijer, and M. Laitinen Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines Anticancer Drugs 13 2002 245 254
28. E. Corey, L.G. Brown, J.E. Quinn, M. Poot, M.P. Roudier, and C.S. Higano Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer Clin Cancer Res 9 2003 295 306 (Erratum in: Clin Cancer Res 2003;9:1574-5)
29. F. Saad, and C.C. Schulman Role of bisphosphonates in prostate cancer Eur Urol 45 2004 26 34
30. A. Berruti, L. Dogliotti, M. Tucci, R. Tarabuzzi, D. Fontana, and A. Angeli Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates J Urol 166 2001 2023 2031
31. A.A. Bryden, J.A. Hoyland, A.J. Freemont, N.W. Clarke, and N.J. George Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases Br J Cancer 86 2002 322 325
32. M. Royuela, M. Ricote, M.S. Parsons, I. Garcia-Tunon, R. Paniagua, and M.P. de Miguel Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate J Pathol 202 2004 41 49
33. C.R. Cooper, and K.J. Pienta Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview Prostate Cancer Prostatic Dis 3 2000 6 12
34. R.S. Taichman, C. Cooper, E.T. Keller, K.J. Pienta, N.S. Taichman, and L.K. McCauley Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone Cancer Res 62 2002 1832 1837
35. M. Noda, and J.J. Camilliere In vivo stimulation of bone formation by transforming growth factor-beta Endocrinology 124 1989 2991 2994
36. T.K. Sampath, J.C. Maliakal, P.V. Hauschka, W.K. Jones, H. Sasak, and R.F. Tucker Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro J Biol Chem 267 1992 20352 20362
37. M.S. Steiner, Z.Z. Zhou, D.C. Tonb, and E.R. Barrack Expression of transforming growth factor-beta 1 in prostate cancer Endocrinology 135 1994 2240 2247
38. S.E. Harris, M.A. Harris, P. Mahy, J. Wozney, J.Q. Feng, and G.R. Mundy Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells Prostate 24 1994 204 211
39. A.S. Alam, A. Gallagher, V. Shankar, M.A. Ghatei, H.K. Datta, and C.L. Huang Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption Endocrinology 130 1992 3617 3624
40. J.J. Yin, K.S. Mohammad, S.M. Kakonen, S. Harris, J.R. Wu-Wong, and J.L. Wessale A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases Proc Natl Acad Sci USA 100 2003 10954 10959
41. H. Mayahara, T. Ito, H. Nagai, H. Miyajima, R. Tsukuda, and S. Taketomi In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats Growth Factors 9 1993 73 80
42. J.E. Oesterling Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate J Urol 145 1991 907 923
43. P. Garnero, N. Buchs, J. Zekri, R. Rizzoll, R.E. Coleman, and P.D. Delmas Markers of bone turnover for the management of patients with bone metastases from prostate cancer Br J Cancer 82 2000 858 864
44. L.M. Demers, L. Costa, and A. Lipton Biochemical markers and skeletal metastases Cancer 88 suppl 2000 2919 2926
45. L.M. Demers, L. Costa, and A. Lipton Biochemical markers and skeletal metastases Clin Orthop 415 special issue 2003 S138 S147
46. N.W. Clarke, J. McClure, and N.J. George Morphometric evidence for bone resorption and replacement in prostate cancer Br J Urol 68 1991 74 80